Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuraxisNRXS +2.31%38 Receivables Turnover is 5.54 as of Mar. 2026. GuruFocus rates NRXS with a GF Score™ of 38/100 and a GF Value™ of $2.94 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 843 Biotechnology companies, Neuraxis ranks better than 90.87% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Neuraxis's Revenue for the
three
months ended in Mar. 2026 was $1.61 Mil. Neuraxis's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.29 Mil.
Hence, Neuraxis's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.54.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Neuraxis Receivables Turnover Related Terms
Neuraxis Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Neuraxis's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRXS vs CSBR, RLYB, CGTX: Receivables Turnover Comparison
For the Biotechnology subindustry, Neuraxis's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuraxis Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuraxis's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Neuraxis's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuraxis (NRXS) has a Receivables Turnover of 5.54 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neuraxis and its competitors. According to the industry distribution chart, Neuraxis ranks #77 out of 843 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Neuraxis' Receivables Turnover too high?
Neuraxis' current Receivables Turnover is 5.54. The Biotechnology industry median Receivables Turnover is 5.26. Neuraxis' value of 5.54 is 5.3% above this industry median. Based on the distribution chart, Neuraxis ranks #77 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuraxis has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuraxis' Receivables Turnover compare to CSBR and RLYB?
According to the Biotechnology industry distribution chart, Neuraxis ranks #77 out of 843 companies for Receivables Turnover. This places Neuraxis in the top 9% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.26. Neuraxis' value of 5.54 is 5.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.26, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuraxis's current Receivables Turnover of 5.54 is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neuraxis and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuraxis's current Receivables Turnover is 5.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuraxis stock overvalued right now?
Based on GuruFocus' analysis, Neuraxis (NRXS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.94, compared to a current price of $7.09 — trading 141.2% above its estimated fair value. The current Receivables Turnover is 5.54 and 5.3% above the Biotechnology industry median of 5.26. Neuraxis' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Neuraxis (NRXS), the current Receivables Turnover is 5.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuraxis (NRXS) Overvalued in 2026?
Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued.
The current stock price of $7.09 is trading 141.2% above its estimated GF Value™ of $2.94.
GuruFocus considers Neuraxis to be Significantly Overvalued.
Key valuation signals for NRXS:
Receivables Turnover: 5.54
GF Value™: $2.94 vs. price of $7.09 (141.2% above fair value)
Industry Position: 5.3% above the Biotechnology median (#77 of 843)
No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
38GF Score
Get the complete analysis for NRXS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXS has been successfully added to your 
